About Cimalgex
Something to smile about when it comes to helping dogs with osteoarthritis or perioperative pain
Cimalgex is non-steroidal anti-inflammatory and contains cimicoxib – a selective COX-2 inhibitor1,2 that offers an effective, convenient and well-tolerated treatment.
Cimicoxib provided substantial improvement in clinical signs of canine OA (pain, locomotion, lameness)
Cimicoxib was found to be as effective as firocoxib by both practitioners and pet owners
No changes in blood urea nitrogen and creatinine levels even at 5 times the recommended dose9
No statistical alterations of hepatic enzymes observed, even in dogs treated with up to 6 times the licenced dose3,4,7,8
No active cimicoxib is eliminated through the trials6
Stable liver parameters
in trials3,4,7,8
Good gastro-intestinal tolerance
trial results8
No treatment related findings (such as erosions, ulcerations or perforations) on endoscopy of the stomach and duodenum at all tested dose levels10
No statistical differences
in the gastric and
gastro-duodenal scores between the control group and
treated animals
Body weight and food or water consumption were not affected by treatment with Cimalgex at any
dose level
Three tablet strengths
Suitable for dogs of all sizes
and weights
8mg, 20mg and 80mg tablets
Multi-scored tablets
Quick and accurate daily dosing,
easy to split
Chewable and pork flavoured
Give with or without food,
taken voluntarily by most dogs11
Treatment of pain and inflammation associated with osteoarthritis once daily for up to 6 months. For longer-term treatment, regular monitoring should be undertaken by the veterinary surgeon
Suitable for adult dogs and puppies from 10 weeks of age5
Management of peri-operative pain associated with orthopaedic or soft-tissue surgeries. One administration 2 hours prior to surgery, followed by 3 to 7 days of treatment
Cimalgex also benefits from a range of support materials and programmes for pet owners, as well as materials to enhance your learning and your clinic.
1. L.A. Sorbera, I. Ramis, Prous Science: Cimicoxib; Drugs of the Future 2004, 29(4): 325-330
2. Pena J: PK-PD relationship between cimicoxib plasmatic concentrations and ex vivo COX1/ COX2 activity; study number n°CIN-341-03
3. E. Grandemange (2013) Field evaluation of the efficacy and the safety of cimicoxib in the relief of perioperative pain in dogs. Journal of Small Animal Practice 54 (6), 304-312. 7. S. Rougier (2008)
4. Assessment of the efficacy and safety of cimicoxib compared to firocoxib in dogs with osteoarthritis. Vetoquinol Study n° V3008C1F1.
5. Cimalgex Summary of Product Characteristics.
6. Pena, Carbó, Merlos: In vivo metabolism of [14C] Cimicoxib in Beagle dog; Vetoquinol study number, CIN31102, 2003.
7. J. Zapatero, A. Casadesus,M. de Luna and C. Santasusagna: Toxicity in Beagle dogs with repeated administration for 5 weeks and a 14 day recovery period. Oral administration; 2002,
8. Vetoquinol study number n°CD01/7674T. 11. H. Voute: 26 week oral (tablets) safety study in the Beagle dog treated with Cimicoxib at 2, 6 and 10 mg/kg/day; 2009, Vetoquinol study number n° 3008T4F1.
9. Casadesus, R. Soria, C. Maraschiello, J. Zapatero:39-week toxicity study in Beagle dogs with repeated oral administration and an 8 week recovery period; 2005, Vetoquinol study number n°CD02/8317T
10. H. Voute: 26 week oral (tablets) safety study in the Beagle dog treated with Cimicoxib at 2, 6 and 10 mg/kg/day; 2009, Vetoquinol study number n° 3008T4F1.
11. E. Benizeau: Comparative evaluation of the acceptance of four NSAIDs in adult dogs. Vetoquinol study number n° V3008T9F1/R.
1. L.A. Sorbera, I. Ramis, Prous Science: Cimicoxib; Drugs of the Future 2004, 29(4): 325-330
2. Pena J: PK-PD relationship between cimicoxib plasmatic concentrations and ex vivo COX1/ COX2 activity; study number n°CIN-341-03
3. E. Grandemange (2013) Field evaluation of the efficacy and the safety of cimicoxib in the relief of perioperative pain in dogs. Journal of Small Animal Practice 54 (6), 304-312. 7. S. Rougier (2008)
4. Assessment of the efficacy and safety of cimicoxib compared to firocoxib in dogs with osteoarthritis. Vetoquinol Study n° V3008C1F1.
5. Cimalgex Summary of Product Characteristics.
6. Pena, Carbó, Merlos: In vivo metabolism of [14C] Cimicoxib in Beagle dog; Vetoquinol study number, CIN31102, 2003.
7. J. Zapatero, A. Casadesus,M. de Luna and C. Santasusagna: Toxicity in Beagle dogs with repeated administration for 5 weeks and a 14 day recovery period. Oral administration; 2002,
8. Vetoquinol study number n°CD01/7674T. 11. H. Voute: 26 week oral (tablets) safety study in the Beagle dog treated with Cimicoxib at 2, 6 and 10 mg/kg/day; 2009, Vetoquinol study number n° 3008T4F1.
9. Casadesus, R. Soria, C. Maraschiello, J. Zapatero:39-week toxicity study in Beagle dogs with repeated oral administration and an 8 week recovery period; 2005, Vetoquinol study number n°CD02/8317T
10. H. Voute: 26 week oral (tablets) safety study in the Beagle dog treated with Cimicoxib at 2, 6 and 10 mg/kg/day; 2009, Vetoquinol study number n° 3008T4F1.
11. E. Benizeau: Comparative evaluation of the acceptance of four NSAIDs in adult dogs. Vetoquinol study number n° V3008T9F1/R.
Vetoquinol UK Limited, Steadings Barn, Pury Hill Business Park, Nr Alderton, Towcester, NN12 7LS
+44 (0) 1280 814500 | uk_office@vetoquinol.com | www.vetoquinol.co.uk
Cimalgex® contains Cimicoxib. Cimicoxib is supplied under licence from PALAU PHARMA, Spain. UK (POM-V). IE (POM). GB/NI/IE, (8mg) Vm 06462/5002 GB, EU/2/10/119/001-004, (30mg) Vm 06462/5000 GB, EU/2/10/119/005-008, (80mg) Vm 06462/5001 GB, EU/2/10/119/009-012.
Further information from the datasheet at www.noahcompendium.co.uk or www.apha.ie/search.aspx or contact Vetoquinol on +44 (0)1280 814500, uk_office@vetoquinol.com. Advice should be sought from the medicine prescriber. Prescription decisions are for the person issuing the prescription alone. Use medicines responsibly.
References available here.
© 2025 Vetoquinol S.A. All Rights Reserved | Privacy and Cookies Policy | General Terms of Use
Cimalgex® is a prescription-only veterinary medicine. This website is intended for veterinary professionals.
Please click the button below to confirm that you are a veterinary professional to proceed.
